Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating molecular profiling data with data from multiple genetic perturbation screens, we identified candidate synthetic lethal (SL) interactions associated with RB1 defects in TNBC. We refined this analysis by identifying the highly penetrant effects, reasoning that these would be more robust in the face of molecular heterogeneity and would represent more promising therapeutic targets. A significant proportion of the highly penetrant RB1 SL effects involved proteins closely associated with RB1 function, suggesting that this might ...
Breast cancer is a multifaceted disease that affects 1 in every 8 women. Triple negative breast canc...
© 2016 Dr. Lily LeeBreast cancer is the most common cancer to affect women, resulting in over half a...
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup ha...
Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor ...
Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concer...
Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by p...
Triple negative breast cancers (TNBC) lack estrogen and progesterone receptors, and HER-2 markers re...
Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor ...
Breast cancer affects one in eight women making it the most common cancer in the United Kingdom, acc...
Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically ch...
International audienceSome mutations in cancer cells can be exploited for therapeutic intervention. ...
Breast cancer affects one in eight women making it the most common cancer in the United Kingdom, acc...
Breast cancers that are triple-negative for the clinical markers ESR1, PGR, and HER2 typically bel...
Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate fr...
Breast cancer is a heterogeneous disease with triple negative breast cancer (TNBC) exhibiting the wo...
Breast cancer is a multifaceted disease that affects 1 in every 8 women. Triple negative breast canc...
© 2016 Dr. Lily LeeBreast cancer is the most common cancer to affect women, resulting in over half a...
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup ha...
Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor ...
Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concer...
Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by p...
Triple negative breast cancers (TNBC) lack estrogen and progesterone receptors, and HER-2 markers re...
Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the RB tumor ...
Breast cancer affects one in eight women making it the most common cancer in the United Kingdom, acc...
Lacking targetable molecular drivers, triple-negative breast cancer (TNBC) is the most clinically ch...
International audienceSome mutations in cancer cells can be exploited for therapeutic intervention. ...
Breast cancer affects one in eight women making it the most common cancer in the United Kingdom, acc...
Breast cancers that are triple-negative for the clinical markers ESR1, PGR, and HER2 typically bel...
Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate fr...
Breast cancer is a heterogeneous disease with triple negative breast cancer (TNBC) exhibiting the wo...
Breast cancer is a multifaceted disease that affects 1 in every 8 women. Triple negative breast canc...
© 2016 Dr. Lily LeeBreast cancer is the most common cancer to affect women, resulting in over half a...
Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup ha...